$INGN
Inogen Inc Stock $ingn

$ingn Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-K Financial Statement

#000156459017002859 Filed on February 28, 2017

Income Statement

Concept	2016 Q4	2016 Q3	2016 Q2
Revenue	$50.90M	$54.40M	$54.57M
YoY Change	25.85%	33.41%	23.93%
Cost Of Revenue	$26.20M	$29.30M	$28.35M
YoY Change	28.43%	82.6%	22.17%
Gross Profit	$24.70M	$25.10M	$26.22M
YoY Change	23.27%	29.55%	25.9%
Gross Profit Margin	48.53%	46.14%	48.04%
Selling, General & Admin	$17.30M	$18.40M	$16.82M
YoY Change	13.07%	26.5%	15.96%
% of Gross Profit	70.04%	73.31%	64.15%
Research & Development	$1.200M	$1.400M	$1.379M
YoY Change	0.0%	25.45%	41.44%
% of Gross Profit	4.86%	5.58%	5.26%
Depreciation & Amortization	$3.270M	$3.420M	$3.420M
YoY Change	-7.63%	-3.93%	-1.44%
% of Gross Profit	13.24%	13.63%	13.05%
Operating Expenses	$18.50M	$19.70M	$18.20M
YoY Change	11.45%	25.79%	17.57%
Operating Profit	$6.200M	$5.400M	$8.019M
YoY Change	80.34%	45.4%	50.03%
Interest Expense	$100.0K	$100.0K	$2.000K
YoY Change		1900.0%	-66.67%
% of Operating Profit	1.61%	1.85%	0.02%
Other Income/Expense, Net	-$400.0K	$0.00	$23.00K
YoY Change	100.0%	-100.0%	-174.19%
Pretax Income	$5.834M	$5.449M	$8.042M
YoY Change	75.88%	48.15%	51.34%
Income Tax	$574.0K	$203.0K	$550.0K
% Of Pretax Income	9.84%	3.73%	6.84%
Net Earnings	$9.600M	$5.246M	$7.492M
YoY Change	148.83%	94.58%	116.59%
Net Earnings / Revenue	18.86%	9.64%	13.73%
Basic Earnings Per Share		$0.26	$0.38
Diluted Earnings Per Share	$0.25	$0.25	$0.36
COMMON SHARES
Basic Shares Outstanding	20.31M	20.16M	19.97M
Diluted Shares Outstanding	21.36M	21.18M	21.00M

Balance Sheet

Concept	2016 Q4	2016 Q3	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$113.9M	$108.3M	$98.10M
YoY Change	37.38%	46.15%	48.41%
Cash & Equivalents	$92.85M	$86.01M	$84.50M
Short-Term Investments	$21.03M	$22.30M	$13.60M
Other Short-Term Assets	$2.100M	$1.900M	$2.900M
YoY Change	61.54%	-75.95%	-59.15%
Inventory	$14.34M	$16.50M	$12.51M
Prepaid Expenses
Receivables	$30.83M	$29.70M	$27.84M
Other Receivables	$500.0K	$1.600M	$1.300M
Total Short-Term Assets	$161.5M	$158.1M	$142.6M
YoY Change	40.63%	38.2%	30.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.20M	$26.80M	$28.44M
YoY Change	-17.86%	-15.46%	-11.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$410.0K	$9.600M	$97.00K
YoY Change	322.68%	-13.51%	-99.37%
Total Long-Term Assets	$52.55M	$53.21M	$54.96M
YoY Change	13.08%	23.47%	14.97%
TOTAL ASSETS
Total Short-Term Assets	$161.5M	$158.1M	$142.6M
Total Long-Term Assets	$52.55M	$53.21M	$54.96M
Total Assets	$214.0M	$211.3M	$197.5M
YoY Change	32.69%	34.17%	25.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.738M	$10.21M	$11.06M
YoY Change	-22.96%	-28.57%	-35.71%
Accrued Expenses	$8.900M	$8.800M	$6.400M
YoY Change	67.92%	91.3%	48.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$100.0K	$159.0K
YoY Change	-100.0%	-67.85%	-47.0%
Total Short-Term Liabilities	$22.85M	$30.20M	$27.98M
YoY Change	3.78%	32.24%	11.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$282.0K	$8.500M	$340.0K
YoY Change	-16.32%	2547.98%	-91.5%
Total Long-Term Liabilities	$282.0K	$8.500M	$340.0K
YoY Change	-16.32%	2019.7%	-91.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.85M	$30.20M	$27.98M
Total Long-Term Liabilities	$282.0K	$8.500M	$340.0K
Total Liabilities	$31.96M	$38.70M	$35.28M
YoY Change	17.09%	40.48%	20.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.36M	-$17.62M	-$22.87M
YoY Change	-72.59%	-64.01%
Common Stock	$194.5M		$185.1M
YoY Change	8.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$182.1M	$172.6M	$162.2M
YoY Change
Total Liabilities & Shareholders Equity	$214.0M	$194.8M	$182.8M
YoY Change	32.69%	23.71%	16.28%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2016 Q2
OPERATING ACTIVITIES
Net Income	$9.600M	$5.246M	$7.492M
YoY Change	148.83%	94.58%	116.59%
Depreciation, Depletion And Amortization	$3.270M	$3.420M	$3.420M
YoY Change	-7.63%	-3.93%	-1.44%
Cash From Operating Activities	$5.180M	$9.050M	$12.02M
YoY Change	-58.76%	-23.63%	56.31%
INVESTING ACTIVITIES
Capital Expenditures	-$230.0K	-$370.0K	-$520.0K
YoY Change	-42.5%	-33.93%	-28.77%
Acquisitions
YoY Change
Other Investing Activities	-$320.0K	-$10.32M	-$1.120M
YoY Change	357.14%	65.12%	-93.51%
Cash From Investing Activities	-$550.0K	-$10.69M	-$1.630M
YoY Change	14.58%	56.74%	-90.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.290M	3.080M	1.820M
YoY Change	-308.18%	-274.01%	82.0%
NET CHANGE
Cash From Operating Activities	5.180M	9.050M	12.02M
Cash From Investing Activities	-550.0K	-10.69M	-1.630M
Cash From Financing Activities	2.290M	3.080M	1.820M
Net Change In Cash	6.920M	1.440M	12.21M
YoY Change	-36.98%	-55.83%	-231.57%
FREE CASH FLOW
Cash From Operating Activities	$5.180M	$9.050M	$12.02M
Capital Expenditures	-$230.0K	-$370.0K	-$520.0K
Free Cash Flow	$5.410M	$9.420M	$12.54M
YoY Change	-58.26%	-24.09%	48.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M5D
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	816800000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66106000
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	16793000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19872000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	591000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-37000
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-459000
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-23000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14012000
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	272000
CY2014	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	5143000
CY2014	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	7898000
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	202000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1451000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1564000
CY2015Q4	us-gaap	Inventory Net InventoryNet	8648000
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	397000
CY2015Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	2158000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	870000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	114844000
CY2015Q4	ingn	Rental Equipment Net Of Allowances RentalEquipmentNetOfAllowances	54677000
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	4680000
CY2015Q4	ingn	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	4503000
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	732000
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	978000
CY2015Q4	ingn	Land And Building LandAndBuilding	125000
CY2015Q4	ingn	Construction In Process ConstructionInProcess	578000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	66273000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35593000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30680000
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19782403
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	42000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14727000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10052000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3142000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3226000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	11585000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	6826000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	55000
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-14000
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-6000
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20997429
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3570000
CY2016	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1725000
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.97
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20067152
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21095867
CY2016	us-gaap	Cost Of Services Depreciation CostOfServicesDepreciation	11429000
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	118671000
CY2014	ingn	Warrants Converted To Temporary Equity Value WarrantsConvertedToTemporaryEquityValue	593000
CY2014	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	987000
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	120251000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1451000
CY2014	ingn	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	61000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	76000
CY2014	ingn	Deemed Dividend On Redeemable Convertible Preferred Stock DeemedDividendOnRedeemableConvertiblePreferredStock	987000
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	49844000
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	1641000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	118150000
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	701000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1615000
CY2015	ingn	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	5000
CY2015	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-1641000
CY2016	ingn	Cumulative Effect Of Change In Accounting Principle CumulativeEffectOfChangeInAccountingPrinciple	12226000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7294000
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1055000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6974000
CY2016	ingn	Gain Loss On Write Off Of Rental Units And Other Fixed Assets GainLossOnWriteOffOfRentalUnitsAndOtherFixedAssets	-1202000
CY2015	ingn	Gain Loss On Write Off Of Rental Units And Other Fixed Assets GainLossOnWriteOffOfRentalUnitsAndOtherFixedAssets	-1214000
CY2014	ingn	Gain Loss On Write Off Of Rental Units And Other Fixed Assets GainLossOnWriteOffOfRentalUnitsAndOtherFixedAssets	-1897000
CY2016	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	11082000
CY2015	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	7598000
CY2016	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	10777000
CY2015	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	8543000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	7294000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3640000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1036000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4760000
CY2015	ingn	Excess Tax Benefit Expense From Share Based Compensation Operating Activities ExcessTaxBenefitExpenseFromShareBasedCompensationOperatingActivities	-1641000
CY2014	ingn	Excess Tax Benefit Expense From Share Based Compensation Operating Activities ExcessTaxBenefitExpenseFromShareBasedCompensationOperatingActivities	1641000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32738000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16699000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22159000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7458000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2570000
CY2015	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	10236000
CY2015	ingn	Excess Tax Benefit Expense From Share Based Compensation Financing Activities ExcessTaxBenefitExpenseFromShareBasedCompensationFinancingActivities	-1641000
CY2014	ingn	Excess Tax Benefit Expense From Share Based Compensation Financing Activities ExcessTaxBenefitExpenseFromShareBasedCompensationFinancingActivities	1641000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7714000
CY2016	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1000
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-118000
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3637000
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1205000
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1168000
CY2016	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	1507000
CY2015	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	858000
CY2014	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	306000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2759000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2030000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2229000
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-11000
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	11000
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-55000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-38000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-80000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	31034000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	38161000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	15697000
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	33142000
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	36626000
CY2016	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	28843000
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	19810000
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	113000
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	45000
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	205000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1718000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2208000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1551000
CY2016	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	6185000
CY2014	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	14481000
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	388000
CY2014	us-gaap	Payments For Other Deposits PaymentsForOtherDeposits	17000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-11927000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-29305000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-16254000
CY2014	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	6000000
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	5000
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	506000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6974000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1615000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	946000
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56471000
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6031000
CY2016	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1055000
CY2015	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	701000
CY2014	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	413000
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	315000
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	299000
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	213000
CY2014	us-gaap	Repayments Of Debt RepaymentsOfDebt	15861000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	381000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	43872000
CY2016	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	-76000
CY2015	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	33000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	26745000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9270000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	43315000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56836000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13521000
CY2016	us-gaap	Interest Paid InterestPaid	10000
CY2015	us-gaap	Interest Paid InterestPaid	26000
CY2014	us-gaap	Interest Paid InterestPaid	487000
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-447000
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	19000
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2061000
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company calls the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 2.8, 4.8 or 7.0 pounds with a single battery. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portable oxygen concentrators represented the fastest-growing segment of the Medicare oxygen therapy market between 2012 and 2015. The Company estimates based on 2015 Medicare data that patients using portable oxygen concentrators represented approximately 8% of the total addressable oxygen market in the United States, although the Medicare data does not account for private insurance and cash-pay sales into the market. Based on 2015 industry data, the Company believes it was the leading worldwide manufacturer of portable oxygen concentrators, as well as the largest provider of portable oxygen concentrators to Medicare patients, as measured by dollar volume. The Company believes it is the only manufacturer of portable oxygen concentrators that employs a direct-to-consumer strategy in the United States, meaning the Company markets its products to patients, processes their physician paperwork, provides clinical support as needed and bills Medicare or insurance on their behalf. To pursue a direct-to-consumer strategy, the Company’s manufacturing competitors would need to meet national accreditation and state-by-state licensing requirements and secure Medicare billing privileges including Medicare competitive bidding contracts, as well as compete with the home medical equipment providers that many rely on across their entire homecare business. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since adopting the Company’s direct-to-consumer strategy in 2009 following its acquisition of Comfort Life Medical Supply, LLC, which had an active Medicare billing number but few other assets and limited business activities, the Company has directly sold or rented more than 228,000 of its Inogen oxygen concentrators as of December 31, 2016.  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the report amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, inventory and rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, warranty expense, stock compensation expense, depreciation and amortization, income tax provision and uncertain tax positions, and fair value of financial instruments.  Actual results could differ from these estimates. </p></div>
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, short-term investments and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation (FDIC). However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents to date. The Company has also entered into hedging relationships with a single counterparty to offset the forecasted Euro based revenues. The credit risk has been reduced due to a net settlement arrangement whereby the Company is allowed to net settle transactions with a single net amount payable by one party to the other.</p></div>
CY2016Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	12382000
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2152000
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	191000
CY2015	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2520000
CY2016	us-gaap	Extended Product Warranty Description ExtendedProductWarrantyDescription	The second deliverable is the lifetime warranty that provides for a functional oxygen concentrator for the remaining lifetime of the patient
CY2015Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2016	ingn	Patients Using Portable Oxygen Concentrators PatientsUsingPortableOxygenConcentrators	0.08
CY2016	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2015	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2014	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2016	ingn	Number Of Deliverables When Lifetime Warranty Is Sold NumberOfDeliverablesWhenLifetimeWarrantyIsSold	2
CY2016	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The first deliverable is the oxygen concentrator equipment which comes with a standard warranty of three years and the additional service component is broken out from the product sales and deferred and recognized in years four and five to correspond with the service period.
CY2016	us-gaap	Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Method RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceMethod	the Company estimates that 60% of its oxygen therapy patients will succumb to their disease within three years of initial diagnosis. Given the approximate mortality rate of 20% per year, the Company estimates on average all patients will succumb to their disease within five years of initial diagnosis.
CY2016	ingn	Standard Warranty Period Offered StandardWarrantyPeriodOffered	P3Y
CY2016	ingn	Product Sales Warranty Period Including Extended Period ProductSalesWarrantyPeriodIncludingExtendedPeriod	P5Y
CY2016Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3480000
CY2015Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1973000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.02
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.19
CY2016Q4	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	6078000
CY2015Q4	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	4115000
CY2016	us-gaap	Revenue Recognition New Accounting Pronouncement Timing RevenueRecognitionNewAccountingPronouncementTiming	30-day period
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	21033000
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	48533000
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	52164000
CY2016Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	39277000
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	6725000
CY2016Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	5041000
CY2015Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	7217000
CY2016Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	39360000
CY2015Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	26017000
CY2016	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	1.000
CY2015	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	1.000
CY2016	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2015	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2016Q4	ingn	Doubtful Accounts DoubtfulAccounts	1869000
CY2015Q4	ingn	Doubtful Accounts DoubtfulAccounts	1664000
CY2016Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	585000
CY2015Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	366000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8532000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6145000
CY2016	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.047
CY2015	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.064
CY2016	ingn	Rental Revenue Adjustments Percentage RentalRevenueAdjustmentsPercentage	0.154
CY2015	ingn	Rental Revenue Adjustments Percentage RentalRevenueAdjustmentsPercentage	0.158
CY2016	ingn	Sales Returns Percentage SalesReturnsPercentage	0.015
CY2015	ingn	Sales Returns Percentage SalesReturnsPercentage	0.014
CY2016	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.216
CY2015	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.236
CY2016	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.706
CY2016	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1454000
CY2015	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1449000
CY2015Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	7097000
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1679000
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	128000
CY2016Q4	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	0
CY2016	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2464000
CY2014	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	1628000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13457000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13926000
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11930000
CY2016Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	725000
CY2015Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	850000
CY2016	us-gaap	Advertising Expense AdvertisingExpense	6215000
CY2015	us-gaap	Advertising Expense AdvertisingExpense	4686000
CY2014	us-gaap	Advertising Expense AdvertisingExpense	3290000
CY2016	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2015	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2016	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2016	ingn	Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend	20519000
CY2015	ingn	Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend	11585000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	20519000
CY2016Q3	us-gaap	Assets Assets	211314000
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30361000
CY2014	ingn	Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend	5839000
CY2014	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	567000
CY2016	ingn	Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock	20519000
CY2015	ingn	Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock	11585000
CY2014	ingn	Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock	5272000
CY2014	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	514000
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	11585000
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	5325000
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	10579
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	128016
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1028715
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1298600
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1726913
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	841760
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	744301
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	546142
CY2016Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	26856000
CY2016Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	26236000
CY2016Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	26037000
CY2016Q1	us-gaap	Assets Assets	180782000
CY2016Q2	us-gaap	Assets Assets	197518000
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22869000
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17623000
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	150571000
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	162235000
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	172605000
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	879000
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	550000
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	203000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	2521000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	7492000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	5246000
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19827669
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19972395
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20157688
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20840367
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21182587
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1429000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1632000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1232000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1003000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	101000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	86000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	33000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	726000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	245000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	451000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1345000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1104000
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-140000
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1139000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	776000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	102000
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	525000
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2015	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	101000
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	150000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	6000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	6000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5738000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7448000
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4290000
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3548000
CY2016Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	1760000
CY2015Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	1581000
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	281000
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	45000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1227000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-38000
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1664000
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1357000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3639000
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2782000
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	590000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	705000
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3000
CY2016	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	1947000
CY2015	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4344000
CY2014	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2785000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	968000
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1164000
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1223000
CY2016	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	979000
CY2015	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	3180000
CY2014	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	1562000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	6199000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4031000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16505000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11874000
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	26654000
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	15464000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0088
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0200
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0247
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0011
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0016
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0011
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	8690000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	6527000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2378000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	982000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33772000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23414000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	767000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1735000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	33005000
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21679000
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6351000
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6215000
CY2016	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.2374
CY2015	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	0.0065
CY2014	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	0.0128
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies State And Local EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal	0.0009
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies State And Local EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal	-0.0003
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies State And Local EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal	-0.0025
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0426
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0791
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1216
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0175
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0297
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0349
CY2016	ingn	Effective Income Tax Rate Reconciliation Net Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration	0.0451
CY2015	ingn	Effective Income Tax Rate Reconciliation Net Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration	0.0117
CY2014	ingn	Effective Income Tax Rate Reconciliation Net Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration	0.0809
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.0311
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0013
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0263
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0204
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0971
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2133
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3209
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	934000
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	773000
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	577000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	773000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	577000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	306000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	161000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	176000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	123000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	20000
CY2016	ingn	Voting Rights Associated With Each Share Of Common Stock VotingRightsAssociatedWithEachShareOfCommonStock	1
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	148000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	934000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2144974
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2295370
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	933707
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2179294
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	683998
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	570079
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	53247
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	515
CY2016	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceExpired	8.70
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.94
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.81
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2328675
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	754916
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	736519
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	80640
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4799
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2261633
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1100539
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.28
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.81
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.09
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.31
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	39.91
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.39
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.28
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.36
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.16
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.15
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	44.70
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.32
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.09
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.70
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.22
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	16.61
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	27.95
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y15D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y8M23D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M17D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11M23D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y6M18D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y11M16D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y5M1D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y11M16D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2013	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	10.23
CY2014	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	24.06
CY2014Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	29.35
CY2014Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	24.18
CY2016Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	50.56
CY2016Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	39.22
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7294000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3640000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1451000
CY2016	ingn	Share Based Compensation Expense Reduced Rate For Estimated Forfeiture ShareBasedCompensationExpenseReducedRateForEstimatedForfeiture	0.069
CY2015	ingn	Share Based Compensation Expense Reduced Rate For Estimated Forfeiture ShareBasedCompensationExpenseReducedRateForEstimatedForfeiture	0.075
CY2014	ingn	Share Based Compensation Expense Reduced Rate For Estimated Forfeiture ShareBasedCompensationExpenseReducedRateForEstimatedForfeiture	0.069
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16057000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12095000
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4948000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0100
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0095
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0132
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0140
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0177
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0202
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4395
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4199
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4215
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4593
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4487
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5273
CY2016	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	6408000
CY2015	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	2428000
CY2014	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	5329000
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2016Q4	ingn	Preferred Stock Warrant Liability PreferredStockWarrantLiability	0
CY2015Q4	ingn	Preferred Stock Warrant Liability PreferredStockWarrantLiability	0
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2016	ingn	Other Comprehensive Income Loss Foreign Currency Transaction Hedging And Available For Sale Investments Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionHedgingAndAvailableForSaleInvestmentsNetOfTax	-35000
CY2015	ingn	Other Comprehensive Income Loss Foreign Currency Transaction Hedging And Available For Sale Investments Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionHedgingAndAvailableForSaleInvestmentsNetOfTax	-37000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1169000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1156000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1155000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	755000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	249000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	21000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4505000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1028000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	750000
CY2016Q4	us-gaap	Purchase Obligation PurchaseObligation	44800000
CY2014Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1115000
CY2013Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	809000
CY2015	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-14000
CY2014Q4	ingn	Number Of Hedging Contract NumberOfHedgingContract	0
CY2016Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	4
CY2015Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	24
CY2016Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	2
CY2016Q1	us-gaap	Revenues Revenues	42989000
CY2016Q2	us-gaap	Revenues Revenues	54567000
CY2016	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3123000
CY2015	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1871000
CY2014	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1075000
CY2016	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	118000
CY2015	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	510000
CY2014	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	406000
CY2016	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1734000
CY2015	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1523000
CY2014	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1175000
CY2016Q4	us-gaap	Former Gain Contingency Recognized In Current Period FormerGainContingencyRecognizedInCurrentPeriod	250000
CY2016Q3	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	1250000
CY2016Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	924000
CY2016	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	47000
CY2016Q1	us-gaap	Gross Profit GrossProfit	21279000
CY2016Q2	us-gaap	Gross Profit GrossProfit	26215000
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3400000
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8042000
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5449000
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5834000
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	574000
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20310857
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21362513
CY2015Q1	us-gaap	Revenues Revenues	33752000
CY2015Q2	us-gaap	Revenues Revenues	44029000
CY2015Q3	us-gaap	Revenues Revenues	40778000
CY2015Q4	us-gaap	Revenues Revenues	40446000
CY2015Q1	us-gaap	Gross Profit GrossProfit	16023000
CY2015Q2	us-gaap	Gross Profit GrossProfit	20822000
CY2015Q3	us-gaap	Gross Profit GrossProfit	19375000
CY2015Q4	us-gaap	Gross Profit GrossProfit	20038000
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2418000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5314000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3678000
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3317000
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	846000
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1855000
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	982000
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-541000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	1572000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	3459000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	2696000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	3858000
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19167585
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19310064
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19428653
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19689662
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20562040
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20672414
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20783550
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20812773

Files In Submission

Name	View Source	Status
0001564590-17-002859-index-headers.html	Edgar Link	pending
0001564590-17-002859-index.html	Edgar Link	pending
0001564590-17-002859.txt	Edgar Link	pending
0001564590-17-002859-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2017022817494262316485.jpg	Edgar Link	pending
g2017022817494972316486.jpg	Edgar Link	pending
ingn-10k_20161231.htm	Edgar Link	pending
ingn-20161231.xml	Edgar Link	completed
ingn-20161231.xsd	Edgar Link	pending
ingn-20161231_cal.xml	Edgar Link	unprocessable
ingn-20161231_def.xml	Edgar Link	unprocessable
ingn-20161231_lab.xml	Edgar Link	unprocessable
ingn-20161231_pre.xml	Edgar Link	unprocessable
ingn-ex1011_175.htm	Edgar Link	pending
ingn-ex1028_174.htm	Edgar Link	pending
ingn-ex231_262.htm	Edgar Link	pending
ingn-ex232_263.htm	Edgar Link	pending
ingn-ex311_173.htm	Edgar Link	pending
ingn-ex312_171.htm	Edgar Link	pending
ingn-ex321_172.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INGN
Inogen Inc Stock $ingn

2016 Q4 Form 10-K Financial Statement

#000156459017002859 Filed on February 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN Inogen Inc Stock $ingn

2016 Q4 Form 10-K Financial Statement

#000156459017002859 Filed on February 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN
Inogen Inc Stock $ingn